Blue Cross Blue Shield insurers are divided over new contentious Alzheimer drug,  Aduhelm. But Anthem, like its competitor UnitedHealth, is currently considering its options. Before making final insurance coverage choices, Anthem CEO Gail Boudreaux maintained they will “continue to examine” the available clinical evidence from the administration around the recently approved medicine.

Read more at DistilINFO Healthplan